Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2041
Título : Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.
Autor : Medrano, Luz María
Taxonera, Carlos
González-Artacho, Cristina
Pascual, Virginia
Gómez-García, María
Barreiro-de Acosta, Manuel
Pérez-Calle, José L
Bermejo, Fernando
López-Sanromán, Antonio
Martín Arranz, Dolores
Gisbert, Javier P
Mendoza, Juan Luis
Martín, Javier
Núñez, Concepción
Urcelay, Elena
Filiación: [Medrano,LM; Pascual,V; Núñez,C; Urcelay,E] Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Taxonera,C; Mendoza,JL] Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [González-Artacho,C; Gómez-García,M] Gastroenterology Department, Virgen de las Nieves Hospital, Granada, Spain. [Barreiro-de Acosta,M] Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. [Perez-Calle,JL] Gastroenterology Department, Alcorcón Hospital, Madrid, Spain. [Bermejo,F] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [López-Sanromán,A] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [Martín Arranz,D] Gastroenterology Department, La Paz Hospital, Madrid, Spain. [Gisber,JP] Gastroenterology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla, Granada, Spain.
Palabras clave : Anticuerpos monoclonales
Marcadores biológicos
Enfermedad de Crohn
Genotipo
Haplotipos
Humanos
Íleon
Colon
Interleucina-11
Polimorfismo genético
Factor de necrosis tumoral alfa
MeSH: Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers
Medical Subject Headings::Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases::Crohn Disease
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Small::Ileum
Medical Subject Headings::Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Large::Colon
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-11
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alpha
Fecha de publicación : 2015
Editorial : Hindawi Publishing Corporation
Cita Bibliográfica: Medrano LM, Taxonera C, González-Artacho C, Pascual V, Gómez-García M, Barreiro-de Acosta M, et al. Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. Mediators Inflamm.; 2015:318207
Abstract: Substantial proportion of Crohn's disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical and economic benefit. The expression profile of five genes (S100A8-S100A9, G0S2, TNFAIP6, and IL11) reportedly predicted response to IFX and we aimed at investigating their etiologic role through genetic association analysis. Patients with active CD (350) who received at least three induction doses of IFX were included and classified according to IFX response. A tagging strategy was used to select genetic polymorphisms that cover the variability present in the chromosomal regions encoding the identified genes with altered expression. Following genotyping, differences between responders and nonresponders to IFX were observed in haplotypes of the studied regions: S100A8-S100A9 (rs11205276* G/rs3014866* C/rs724781* C/rs3006488* A; P = 0.05); G0S2 (rs4844486* A/rs1473683* T; P = 0.15); TNFAIP6 (rs11677200* C/rs2342910* A/rs3755480* G/rs10432475* A; P = 0.10); and IL11 (rs1126760* C/rs1042506* G; P = 0.07). These differences were amplified in patients with colonic and ileocolonic location for all but the TNFAIP6 haplotype, which evidenced significant difference in ileal CD patients. Our results support the role of the reported expression signature as predictive of anti-TNF outcome in CD patients and suggest an etiological role of those top-five genes in the IFX response pathway.
Descripción : Journal Article; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/2041
Versión del editor : http://www.hindawi.com/journals/mi/2015/318207/abs/
DOI: 10.1155/2015/318207
ISSN : 1466-1861 (Online)
0962-9351 (Print)
Appears in Collections:01- Artículos - Hospital Virgen de las Nieves

Files in This Item:
File Description SizeFormat 
Medrano_ResponseToInfliximab.pdfArtículo publicado1,32 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons